CA3262851A1 - Binding proteins to the human thrombin receptor, par4 - Google Patents
Binding proteins to the human thrombin receptor, par4Info
- Publication number
- CA3262851A1 CA3262851A1 CA3262851A CA3262851A CA3262851A1 CA 3262851 A1 CA3262851 A1 CA 3262851A1 CA 3262851 A CA3262851 A CA 3262851A CA 3262851 A CA3262851 A CA 3262851A CA 3262851 A1 CA3262851 A1 CA 3262851A1
- Authority
- CA
- Canada
- Prior art keywords
- par4
- binding proteins
- thrombin receptor
- human thrombin
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017903685 | 2017-09-11 | ||
| AU2017903685A AU2017903685A0 (en) | 2017-09-11 | Antagonists of the human thrombin receptor, PAR4 | |
| CA3075523A CA3075523A1 (en) | 2017-09-11 | 2018-09-11 | Binding proteins to the human thrombin receptor, par4 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3075523A Division CA3075523A1 (en) | 2017-09-11 | 2018-09-11 | Binding proteins to the human thrombin receptor, par4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3262851A1 true CA3262851A1 (en) | 2026-03-02 |
Family
ID=65633328
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3262851A Pending CA3262851A1 (en) | 2017-09-11 | 2018-09-11 | Binding proteins to the human thrombin receptor, par4 |
| CA3075523A Pending CA3075523A1 (en) | 2017-09-11 | 2018-09-11 | Binding proteins to the human thrombin receptor, par4 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3075523A Pending CA3075523A1 (en) | 2017-09-11 | 2018-09-11 | Binding proteins to the human thrombin receptor, par4 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11780915B2 (https=) |
| EP (2) | EP3681911B1 (https=) |
| JP (2) | JP7733443B2 (https=) |
| KR (1) | KR102755742B1 (https=) |
| CN (1) | CN111670198B (https=) |
| AU (1) | AU2018328764B2 (https=) |
| CA (2) | CA3262851A1 (https=) |
| DK (1) | DK3681911T3 (https=) |
| ES (1) | ES2999094T3 (https=) |
| FI (1) | FI3681911T3 (https=) |
| HR (1) | HRP20241684T1 (https=) |
| HU (1) | HUE069649T2 (https=) |
| IL (1) | IL273202B2 (https=) |
| LT (1) | LT3681911T (https=) |
| PT (1) | PT3681911T (https=) |
| SI (1) | SI3681911T1 (https=) |
| WO (1) | WO2019046912A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111670198B (zh) | 2017-09-11 | 2023-12-15 | 莫纳什大学 | 人凝血酶受体par4的结合蛋白 |
| CN112852958A (zh) * | 2021-04-04 | 2021-05-28 | 吉林大学 | 一种检测替格瑞洛抗血小板效果的试剂盒 |
| CN115558015B (zh) * | 2022-10-12 | 2024-01-19 | 生工生物工程（上海）股份有限公司 | 一种从gst融合蛋白酶切后的产物中纯化无gst标签的目的蛋白的方法和产品 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676A (en) | 1846-07-31 | roller | ||
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| SE8804074D0 (sv) | 1988-11-10 | 1988-11-10 | Pharmacia Ab | Sensorenhet och dess anvaendning i biosensorsystem |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| SG41929A1 (en) | 1992-09-25 | 1997-08-15 | Commw Scient Ind Res Org | Target binding polypeptide |
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| US5485277A (en) | 1994-07-26 | 1996-01-16 | Physical Optics Corporation | Surface plasmon resonance sensor and methods for the utilization thereof |
| US5567301A (en) | 1995-03-01 | 1996-10-22 | Illinois Institute Of Technology | Antibody covalently bound film immunobiosensor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| ES2294799T3 (es) | 1996-06-27 | 2008-04-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU2672899A (en) | 1998-02-27 | 1999-09-15 | Regents Of The University Of California, The | Protease-activated receptor 4 and uses thereof |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US6111075A (en) * | 1998-04-01 | 2000-08-29 | Zymogenetics, Inc. | Protese-activated receptor PAR4 (ZCHEMR2) |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| DE19818790A1 (de) | 1998-04-27 | 1999-10-28 | Affina Immuntechnik Gmbh | Immunadsorptionsmatrix, Verfahren zu ihrer Herstellung und ihre Verwendung |
| PT1308456E (pt) | 1998-05-06 | 2007-12-03 | Genentech Inc | Purificação de anticorpos por cromatografia de permuta iónica |
| US6190908B1 (en) | 1998-08-12 | 2001-02-20 | The Scripps Research Institute | Modulation of polypeptide display on modified filamentous phage |
| US6306610B1 (en) | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2378473A1 (en) * | 1999-07-23 | 2001-02-01 | The Regents Of The University Of California | Modulation of platelet activation |
| US20060228364A1 (en) | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| DE60140474D1 (de) | 2000-09-08 | 2009-12-24 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
| AU2002220577A1 (en) | 2000-09-28 | 2002-04-08 | Affina Immuntechnik Gmbh | Circulatory device for separating substances in bodily fluids, especially blood,and the use of said device |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| DK1390535T3 (da) | 2001-04-26 | 2010-12-06 | Amgen Mountain View Inc | Kombinatoriske biblioteker af monomer-domæner |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| AU2004245038A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
| US7993650B2 (en) | 2003-07-04 | 2011-08-09 | Affibody Ab | Polypeptides having binding affinity for HER2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| CN1946417A (zh) | 2003-12-05 | 2007-04-11 | 阿德内克休斯治疗公司 | 2型血管内皮生长因子受体的抑制剂 |
| EA012622B1 (ru) | 2004-06-01 | 2009-10-30 | Домэнтис Лимитед | Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки |
| AU2005250055B2 (en) | 2004-06-02 | 2008-09-11 | Adalta Pty Ltd | Binding moieties based on shark IgNAR domains |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
| US7879792B2 (en) | 2005-06-02 | 2011-02-01 | The Regents Of The University Of Michigan | Synthetic peptide inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4 |
| EP1746161A1 (en) | 2005-07-20 | 2007-01-24 | Cytheris | Glycosylated IL-7, preparation and uses |
| KR20080068004A (ko) | 2005-08-15 | 2008-07-22 | 아라나 테라퓨틱스 리미티드 | 뉴 월드 영장류 구조형성영역을 가진 조작 항체 |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| EP2376109B1 (en) | 2008-12-19 | 2019-01-23 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| US10817851B2 (en) | 2009-12-23 | 2020-10-27 | Aristocrat Technologies Australia Pty Limited | System and method for cashless gaming |
| EP2367000A1 (en) | 2010-03-04 | 2011-09-21 | Charité Universitätsmedizin Berlin | High throughput analysis of T-cell receptor repertoires |
| WO2013163244A1 (en) | 2012-04-26 | 2013-10-31 | Bristol-Myers Squibb Company | Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| CN111670198B (zh) | 2017-09-11 | 2023-12-15 | 莫纳什大学 | 人凝血酶受体par4的结合蛋白 |
-
2018
- 2018-09-11 CN CN201880072254.0A patent/CN111670198B/zh active Active
- 2018-09-11 PT PT188532618T patent/PT3681911T/pt unknown
- 2018-09-11 KR KR1020207010495A patent/KR102755742B1/ko active Active
- 2018-09-11 CA CA3262851A patent/CA3262851A1/en active Pending
- 2018-09-11 WO PCT/AU2018/050985 patent/WO2019046912A1/en not_active Ceased
- 2018-09-11 AU AU2018328764A patent/AU2018328764B2/en active Active
- 2018-09-11 DK DK18853261.8T patent/DK3681911T3/da active
- 2018-09-11 JP JP2020535276A patent/JP7733443B2/ja active Active
- 2018-09-11 HU HUE18853261A patent/HUE069649T2/hu unknown
- 2018-09-11 IL IL273202A patent/IL273202B2/en unknown
- 2018-09-11 US US16/646,554 patent/US11780915B2/en active Active
- 2018-09-11 EP EP18853261.8A patent/EP3681911B1/en active Active
- 2018-09-11 LT LTEPPCT/AU2018/050985T patent/LT3681911T/lt unknown
- 2018-09-11 ES ES18853261T patent/ES2999094T3/es active Active
- 2018-09-11 SI SI201831187T patent/SI3681911T1/sl unknown
- 2018-09-11 HR HRP20241684TT patent/HRP20241684T1/hr unknown
- 2018-09-11 EP EP24208786.4A patent/EP4512469A3/en active Pending
- 2018-09-11 CA CA3075523A patent/CA3075523A1/en active Pending
- 2018-09-11 FI FIEP18853261.8T patent/FI3681911T3/fi active
-
2023
- 2023-05-29 JP JP2023087663A patent/JP2023116543A/ja active Pending
- 2023-08-30 US US18/240,347 patent/US12441790B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3681911T (pt) | 2024-12-18 |
| DK3681911T3 (da) | 2024-12-09 |
| SI3681911T1 (sl) | 2025-01-31 |
| IL273202B1 (en) | 2024-04-01 |
| HRP20241684T1 (hr) | 2025-02-14 |
| US12441790B2 (en) | 2025-10-14 |
| AU2018328764A1 (en) | 2020-04-02 |
| HUE069649T2 (hu) | 2025-04-28 |
| LT3681911T (lt) | 2025-01-10 |
| EP3681911B1 (en) | 2024-11-27 |
| US11780915B2 (en) | 2023-10-10 |
| JP2020533022A (ja) | 2020-11-19 |
| IL273202A (en) | 2020-04-30 |
| CN111670198B (zh) | 2023-12-15 |
| US20210179707A1 (en) | 2021-06-17 |
| WO2019046912A1 (en) | 2019-03-14 |
| IL273202B2 (en) | 2024-08-01 |
| JP2023116543A (ja) | 2023-08-22 |
| EP3681911A4 (en) | 2021-06-02 |
| KR102755742B1 (ko) | 2025-01-15 |
| FI3681911T3 (fi) | 2024-12-30 |
| EP3681911A1 (en) | 2020-07-22 |
| KR20200063159A (ko) | 2020-06-04 |
| AU2018328764B2 (en) | 2025-01-09 |
| CN111670198A (zh) | 2020-09-15 |
| CA3075523A1 (en) | 2019-03-14 |
| US20240117031A1 (en) | 2024-04-11 |
| EP4512469A3 (en) | 2025-05-21 |
| JP7733443B2 (ja) | 2025-09-03 |
| EP4512469A2 (en) | 2025-02-26 |
| ES2999094T3 (en) | 2025-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3572429A4 (en) | POLYPEPTIDE OR COMPOSITE BINDER PD-L1 | |
| EP3630183A4 (en) | PROTEIN THAT BINDING NKG2D, CD16 AND ROR1 OR ROR2 | |
| EP3247724B8 (en) | Il-17a binding proteins | |
| EP3324996A4 (en) | GDF11 BINDING PROTEINS AND USES THEREOF | |
| EP3578570A4 (en) | MULTIFUNCTIONAL PROTEIN | |
| EP3270945A4 (en) | Selective mcl-1 binding peptides | |
| EP3290441A4 (en) | RGMa BINDING PROTEIN AND USE THEREOF | |
| EP3315513A4 (en) | Cd154 binding polypeptide and use thereof | |
| EP3568408A4 (en) | ELASTOMER PROTEINS | |
| EP3653063A4 (en) | PEPTIDE | |
| EP3463414A4 (en) | PROTEIN INTERFACES | |
| EP3309169A4 (en) | Antibody binding specifically to isolated vimentin-derived peptide, or binding fragment of the peptide | |
| IL273202A (en) | Human thrombin receptor binding proteins, PAR4 | |
| EP3583134A4 (en) | NEW MULTI-SPECIFIC BINDING PROTEINS | |
| EP3684856B8 (de) | Dachbahn | |
| EP3224260A4 (en) | Light-activated two-component protein binding matrix | |
| HK40029215A (zh) | 结合ror2的人抗体 | |
| AU2017903685A0 (en) | Antagonists of the human thrombin receptor, PAR4 | |
| HK40019113A (en) | Il-1r-i binding polypeptide | |
| HK40018957A (en) | Binding proteins 1 | |
| HK40029796A (en) | Agonist antibodies that bind human cd137 and uses thereof | |
| EP3801257A4 (en) | OXYMETRY SYSTEM SELF-TEST | |
| HK40027696A (en) | Polypeptide | |
| HK40025429A (en) | Anti-jagged1 antigen binding proteins | |
| HK40013497A (en) | Binding peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL Effective date: 20250121 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250121 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250121 |
|
| A18 | Application divided or continuation or continuation in part accepted |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250207 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250207 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250207 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250207 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250210 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P145 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - DEFECT(S) Effective date: 20250228 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250506 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250903 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250905 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260116 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20260302 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20260305 |